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(p ¼ 0.007). Multivariate Cox regression analysis revealed a decreased
LVGFI as an independent predictor for MACE (hazard ratio ¼ 5.24, 95
% CI 1.70-16.17, p ¼ 0.004) after adjusting for microvascular obstruc-
tion, multivessel disease and diabetes. In ROC analysis, LVGFI was a
strong predictor for MACE (AUC ¼ 0.73, CI 0.61-0.85). The predictive
value of LVEF was similar (AUC ¼ 0.74, CI 0.61-0.87).
CONCLUSIONS LVGFI assessed by CMR is a strong predictor of MACE
within 3 years after ﬁrst STEMI.
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BACKGROUND The pan-London PPCI network uses a 24/7 “Paramedic
Activated” service model with the London Ambulance Service (LAS)
across 8 Cardiac Centres - paramedics autonomously activate the PPCI
service from the community. This model aims to reduce ischemia time
by autonomous paramedic activation. Our Centre also serves a
catchment area surrounding London in which a “Cardiologist
Screened” service model is used in conjunction with the South East
Coast Ambulance Service (SECAMB) - paramedics telemetry link an
ECG to our Centre and discuss the case with the on-call Cardiologist. If
the case does not meet STEMI criteria, the SECAMB crew is redirected
to the nearest ED. This model intends to rationalize the number of
false activations in a catchment area with a much larger geographical
distribution (and therefore transfer times) than London. There are no
previous reports comparing a dual PPCI activation model within one
Centre. We compared the False Activation rates between our two
service models, as a metric of quality.
METHODS Over a 20-month period (January 2013 – August 2014) there
were 2077 consecutive activations of our PPCI service. Cases were
categorized by source of activation - Paramedic Activated (LAS) or
Cardiologist Screened (SECAMB, cardiac center ED or non-cardiac
center ED). Cases were also categorized as True Activations (STEMI
with PPCI or emergency CABG) or as False Activation (not STEMI, but
may have undergone emergency angiography).
RESULTS 942 (45.3%) cases were Paramedic Activated via LAS (LAS
Cohort) and 1038 (50.0%) cases were Cardiologist Screened via
SECAMB (SECAMB Cohort). 24 (1.2%) patients self presented to our ED
and 73 (3.5%) to local EDs – both were excluded from further analysis
for the purpose of comparing the two ambulance service models. The
proportion of False Activations was signiﬁcantly higher in the in the
SECAMB cohort compared to the LAS cohort: SECAMB 805 patients
(77.6%) and LAS 470 patients (49.9%); c2 164.8 (p<0.001). 708/1038 of
the SECAMB activations did not meet STEMI criteria were diverted to
local EDs. Of the SECAMB activations actually transferred to our
Centre (330 cases), the False Activation rate was signiﬁcantly lower
compared to the LAS Cohort: SECAMB 97 patients (29.4%) and LAS
470 patients (49.9%); c2 41.6 (p<0.001).LAS SECAMBCardiac
Centre EDNon-Cardiac
Centre EDTrue Activations 472 233 16 45False Activations 470 805 8 28Total Activations 942 1038 24 73False Activation
Rate49.9% 77.6% 33.3% 38.4%CONCLUSIONS On initial inspection our data does not support the
notion that a Cardiologist Screened service should have a lower False
Activation rate than a Paramedic Activated service. However once
diverted SECAMB referrals are excluded, the False Activation rate is
lower in the Cardiology Screened pathway. Our study highlights an
interesting portal to examine quality of PPCI activation service
models.
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BACKGROUND Poor R-wave progression (PRWP) on electrocardio-
grams has been reported to be associated with old myocardial
infarction (MI) due to an occlusion of the left anterior descending
(LAD) artery. However, PRWP can be observed in patients presenting
with acute MI who do not have history of MI. We hypothesized that
PRWP on admission electrocardiograms predict LAD culprit in our
cohort of patients with non-ST-segment Elevation Myocardial
Infarction (NSTEMI).
METHODS We performed a retrospective analysis of 481 consecutive
NSTEMI patients who underwent coronary angiography from January
2013 to June 2014. Patients with ventricular paced rhythm and bundle
branch block were excluded. In addition, patients with history of MI,
coronary artery bypass grafting, or heart failure were excluded.
Electrocardiograms on admission were interpreted in a blinded
fashion, and PRWP was deﬁned as a R-wave amplitude <3mm in lead
V3 on presenting electrocardiograms. Patients were divided into those
with and without PRWP. An independent cardiologist blinded to the
clinical data visually interpreted all coronary angiograms. LAD culprit
was deﬁned as LAD stenosis70% with either thrombus or ulcerative
base. Baseline and angiographic characteristics were recorded. In
addition, in-hospital heart failure, in-hospital and 30-day major
adverse cardiac events (MACE) including death, recurrent myocardial
infarction, ventricular ﬁbrillation, and target vessel revascularization
were recorded and compared between the two groups.
RESULTS Among 310 patients included in the ﬁnal analysis, 73 pa-
tients (23.5%) had PRWP. No statistically signiﬁcant difference was
observed in baseline characteristics between the two groups. Patients
with PRWP had a higher rate of Killip class>1 on admission than those
without (17.8% vs. 8.9%, p¼0.032). Although peak troponin I values
were comparable between the two groups (median [interquartile];
0.61 [0.15-3.38] ng/ml vs. 0.92 [0.13-6.47] ng/ml, p¼0.58), patients
with PRWP had a lower left ventricular ejection fraction than those
without (57 [39-60] % vs. 60 [55-65] %, p¼ 0.004). With respect to
angiographic ﬁnding, patients with PRWP had a higher rate of LAD
culprit than those without (35.6% vs. 23.2%, p¼0.035). The incidence
of in-hospital heart failure was higher in patients with PRWP than
those without (20.5% vs. 9.3%, p¼0.009). There was a trend toward a
higher incidence of in-hospital MACE (4.1% vs. 1.7%, p¼0.36) and 30-
day MACE (8.2% vs. 3.4%, p¼0.10) in patients with PRWP.
CONCLUSIONS In our cohort of patients with NSTEMI, PRWP on
admission electrocardiograms was associated with the presence of
LAD culprit. There was a trend toward a higher incidence of in-hos-
pital and 30-day MACE in patients with PRWP.
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BACKGROUND ADAMTS13 is a metalloprotease that cleaves von Wil-
lebrand factor (VWF), thereby reducing its prothrombotic properties.
There is considerable evidence that VWF levels increase and
ADAMTS13 levels decrease in STEMI patients. It is unclear if this
contributes to no reﬂow, infarct size and intramyocardial hemorrhage
(IMH). The aim of this study was to determine the role of ADAMTS13 in
patients with acute myocardial infarction; and to investigate the
beneﬁts of recombinant (r)ADAMTS13 in a porcine model of myocar-
dial ischemia-reperfusion with dual antiplatelet therapy and heparin.
METHODS In 49 consecutive PCI-treated STEMI patients, blood sam-
ples were collected directly after and up to 7 days following PCI.
B92 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5Cardiac magnetic resonance was performed 4-6 days after PCI to
determine infarct size and IMH. In 23 Yorkshire swine, the circumﬂex
coronary artery was occluded for 75 minutes by a balloon catheter.
rADAMTS13 or vehicle was administered intracoronary following
reperfusion. Myocardial injury and infarct characteristics were
assessed using cardiac enzymes, ECG, and histopathology.
RESULTS In patients with IMH, VWF activity and VWF antigen were
signiﬁcantly elevated directly after PCI and for all subsequent mea-
surements, and ADAMTS13 activity signiﬁcantly decreased at 4 and 7
days following PCI; in comparison to patients without IMH. VWF ac-
tivity and ADAMTS13 activity were not related to infarct size. For
rADAMTS13 treated animals no differences in myocardial infarct size,
IMH, or formation of microthrombi were witnessed in comparison to
controls.
CONCLUSIONS No correlation was witnessed between VWF/
ADAMTS13 and infarct size in patients; and intracoronary adminis-
tration of rADAMTS13 did not decrease infarct size or IMH in a porcine
model of myocardial ischemia-reperfusion. These data dispute the
imbalance in ADAMTS13 and VWF as the cause of no reﬂow. Restoring
the imbalance between ADAMTS13 and VWF most likely will not be
beneﬁcial in STEMI patients already treated with standard antiplatelet
and anticoagulant therapy.
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BACKGROUND Randomized clinical trials evaluating the role of
thrombus aspiration (TA) in patients undergoing primary percuta-
neous coronary intervention (PPCI) for ST-segment elevation
myocardial infarction (STEMI) have yielded contrasting results.
Therefore, the efﬁcacy and safety of TA in STEMI is unclear.
METHODS We included study-level data from 25 randomized
controlled trials (RCTs), involving 21,733 patients with STEMI and
PPCI. The primary efﬁcacy endpoint was MACE according to study
deﬁnitions; the primary safety endpoint was stroke. We sought to
evaluate the efﬁcacy and safety of TA during PPCI for STEMI
compared with conventional PPCI alone.
RESULTS The mean weighted follow-up time across studies was 8.2
months. Compared with conventional PPCI, TA was associated with
signiﬁcant lower risk for MACE (Relative Risk [RR]: 0.91; 95% Conﬁ-
dence Interval [CI]: 0.83 – 1.00; p ¼ 0.042). However, this beneﬁt in
MACE was counterbalanced by a signiﬁcant increase in the risk for
stroke (RR: 1.58; 95% CI: 1.11 – 2.25; p ¼ 0.011). There were no differ-
ences in the risk of myocardial infarction (RR: 0.94; 95% CI: 0.78 – 1.12;p ¼ 0.486), target vessel revascularization (RR: 0.93; 95% CI: 0.82 –
1.04; p ¼ 0.2) and deﬁnite or probable stent thrombosis (RR: 0.84; 95%
CI: 0.66 – 1.07; p ¼ 0.148). TA was associated with an ostensible lower
risk for all-cause mortality, which did not reach statistical signiﬁcance
(RR: 0.88; 95% CI: 0.78 – 1.00; p ¼ 0.059).
CONCLUSIONS Compared with conventional PPCI for STEMI,
adjunctive TA reduces the risk of subsequent MACE. However, the
beneﬁt in MACE is counterbalanced by an increased risk in stroke.
Considering the above potential risks and beneﬁts, TA should be
considered in selected patients lesions rather than routinely.
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BACKGROUND Prior studies have found that smokers with ST-
segment elevation myocardial infarction (STEMI) have lower rates of
mortality and adverse events. This phenomenon has been called “the
smoker’s paradox.” We sought to investigate the impact of smoking
